As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Boehringer gets diggi with it.